This page shows the latest financial results 2012 news and features for those working in and with pharma, biotech and healthcare.
Profits have declined since 2008, however, when Teva and Barr Pharmaceuticals won a patient challenge to launch their own generic copy, and Nasacort AQ achieved revenues of just 71m during 2012 ... This is part of a wider plan to build its consumer
Sales and profits on track amid job cuts and restructuring. Germany's Merck KGaA successfully navigated a tricky path in 2012 as it kept sales and profits on target, despite ... The restructuring programme is already yielding results in terms of Merck's
to 39.8bn for 2012. ... This helped overcome a decline in sales of the Yaz contraceptive franchise, which lost patent exclusivity during 2012.
yesterday to discuss the deal and Mylan's fourth-quarter results. ... The agreement comes as Mylan reported record financial results in 2012, with revenues up 14 per cent to $6.8bn on the back of 600 product launches around the world, and
Speaking at the presentation of the Belgium-based pharma company's 2012 financial results, Doliveux (pictured) said the ongoing debate over transparency was of little interest outside the UK, and that
2012 in its first set of results since the merger. ... Actavis stopped selling its generic atorvastatin last month because of the "significant decline in the US market for this product in 2012", said Actavis chief financial officer Todd Joyce on the
More from news
Approximately 17 fully matching, plus 6 partially matching documents found.
Accession was a born from a passion and a vision. A passion to harness the power of market access to...